Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

Patients with connective tissue disease-related interstitial lung disease show slower decline in lung function and longer ...

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease characterized by progressive decline in lung function. 1 The pathogenesis of IPF is thought to involve aberrant wound ...

The study aims to advance the development of a potential novel treatment for patients living with idiopathic pulmonary fibrosis, and targets the myofibroblast, the key pathogenic cell in fibrosis.

More information: Luca Richeldi et al, Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2414108 Journal information: New ...

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J ...

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis. PR Newswire. BOSTON, June 5, 2025. First-in-class agent targets WISP1 in patients with IPF ...